NEW YORK and SAN FRANCISCO, March 11, 2019 — Arcline Investment Management, LP ("Arcline" or the "Firm"), a private equity firm established in September 2018, has closed its first investment fund, Arcline Capital Partners LP, at $1.5 billion. Arcline's investor base is primarily comprised of university endowments, sovereign wealth funds, family offices and charitable foundations.

Rajeev Amara, CEO of Arcline said, "We want to thank our investors for entrusting us with their capital. At Arcline, we hope to continue our team's historical record of achieving strong returns by investing in competitively differentiated market leaders and partnering with management teams who can create value by driving organic revenue and earnings growth."

About Arcline Investment Management
Founded in 2018, Arcline is a private equity firm with $1.5 billion of capital under management. The Firm invests in control buyouts of niche, high-quality middle-market businesses operating across a wide range of industries. Arcline targets companies valued up to $1 billion and has offices in San Francisco and New York.

LONG BEACH, CALIFORNIA, July 15, 2019 —Arcline Investment Management ("Arcline"), a growth oriented private equity firm with $1.5 billion of capital under management, today announced that it has acquired Integrated Polymer Solutions, Inc. ("IPS" or "the Company") from Industrial Growth Partners.

IPS utilizes advanced materials to manufacture custom, highly-engineered elastomeric components, such as seals, gaskets and tooling for composite manufacturing, for the aerospace, military, biopharma and specialty industrial end markets. IPS' extensive inventory of 6,000 custom tools are used to produce more than 12,000 components, including thousands of propriety designs, which are sold to more than 1,100 customers. The Company maintains a global manufacturing footprint, with production facilities in Long Beach, California and Sheffield, United Kingdom.

Arcline commented, "IPS' world-class materials science capabilities and significant intellectual property enable the Company to design custom products that solve complex challenges for its highly demanding, global customer base. In fact, many of the most important aerospace programs in the world use IPS products, including the F-35, Boeing 787 and Airbus A350. We're excited to partner with IPS management to build upon the Company's current momentum to achieve breakout growth through organic and inorganic means."

Rich McManus, President and CEO of IPS, added, "We celebrate a new milestone today as we formally join the Arcline family. Combined with Arcline's powerful backing and our shared vision, we will draw on our decades of experience to continue on our journey of growth and new product development, while we remain focused on delivering outstanding customer service to the markets we serve."

William Blair served as financial advisor to Arcline in connection with the acquisition.

About Arcline Investment Management
Arcline is a private equity firm with $1.5 billion in capital, investing in niche, market-leading companies that we are passionate about growing. We approach investments from multiple perspectives, but share a single vision — to identify and unlock the breakout potential in our companies. While we are deliberately sector generalists, some of our primary interest areas include Industrials, Technology, Life Sciences, and Specialty Chemicals.

About Integrated Polymer Solutions
Integrated Polymer Solutions is a leader in designing and engineering elastomeric components and tools for aerospace, military, biopharma and specialty industrial markets. The Company's products utilize advanced materials designed to exceptionally tight tolerances for high-performance applications. IPS' products include elastomeric seals, gaskets, tooling, ablatives, EMI/RFI/thermal shielding products, encapsulated o-rings, and composite APU plenums and ducts. The Company maintains a global manufacturing footprint, with production facilities in Long Beach, California and Sheffield, United Kingdom.

HOUSTON, July 31, 2019 — Arcline Investment Management ("Arcline"), a growth oriented private equity fund with $1.5 billion of capital under management, today announced that it has acquired the Reciprocating Compression division of Baker Hughes, a GE company (NYSE: BHGE).

The Reciprocating Compression division ("the Company") manufactures and services mission-critical compression and engine systems that are used in a variety of applications, including the transmission of natural gas across domestic and international pipelines. The Company is the original equipment manufacturer and supplier of parts for its systems and provides overhaul and repair services to its customers. These customers operate a large installed base of its highly respected brands, including Cooper-Bessemer, Ajax, Superior, Gemini, Enterprise, TSI, CSI, TXC, and Joy. Manufacturing is conducted in its facilities in Houston, TX and Salina, KS, while on-site services are delivered through its extensive network of field technicians operating out of five fully equipped repair and overhaul shops strategically located around the U.S.

Arcline commented, "BHGE's Reciprocating Compression division serves the most critical infrastructure applications of its customers. We plan to aggressively invest in our long standing, loyal employee base so that they can support every brand of our equipment operating in the field."

Robert W. Baird & Co. served as financial advisor to Arcline in connection with the acquisition.

About Arcline Investment Management
Arcline is a private equity firm with $1.5 billion in capital, investing in niche, market-leading companies that we are passionate about growing. We approach investments from multiple perspectives, but share a single vision — to identify and unlock the breakout potential in our companies. While we are deliberately sector generalists, some of our primary interest areas include Industrials, Technology, Life Sciences, and Specialty Chemicals.

SAN FRANCISCO, CA, July 30, 2019 — Arcline Investment Management ("Arcline"), a growth oriented private equity firm with $1.5 billion of capital under management, today announced the formation of a strategic relationship with Dark Horse Consulting Group ("Dark Horse" or "the Company"). Taking the form of an investment in Dark Horse, Arcline's commitment enables the Company to significantly expand its business and accelerate the availability of cost-effective cGMP products and services to the rapidly growing cell and gene therapy field.

Dark Horse is the leading global consultancy practice specializing in cell and gene therapy product development. The Company's services have been used by over 100 industry leading life sciences clients to enhance their business intelligence, quality, manufacturing, regulatory, technology transfer and supply-chain practices.

"The recent maturation of the cell and gene therapy space has resulted in numerous bottlenecks in Chemistry, Manufacturing and Controls ("CMC") for developers. As the global leader in cell and gene therapy CMC consulting services, Dark Horse has experienced rapidly increasing growth from its client base. Arcline's investment will allow us to meet the burgeoning demands of our customers, to the benefit of all in the field," said Anthony Davies, founder and CEO of Dark Horse.

Arcline commented, "Our partnership with Dark Horse demonstrates our commitment to the emerging regenerative medicine industry. We look forward to working closely with Dark Horse to solve critical industry-wide manufacturing bottlenecks, speeding patient access to these revolutionary therapies."

About Arcline Investment Management
Arcline is a private equity firm with $1.5 billion in capital, investing in niche, market-leading companies that we are passionate about growing. We approach investments from multiple perspectives but share a single vision – to identify and unlock the breakout potential in our companies. Some of our primary interest areas include Life Sciences, Industrials, Technology, and Specialty Chemicals.

About Dark Horse Consulting Group
Dark Horse Consulting Group is the leading global consultancy practice in the development of cell and gene therapy products, having served over 100 customers in this field since inception. Its consultants bring over 100 years of combined experience specific to the cell and gene therapy industry, having deep CMC experience, focused on Advanced Therapeutic Medicinal Products (ATMPs) and their regulation by the FDA, the EMA and other jurisdictions. Further specializations include process development, device development, manufacturing, quality, preclinical, regulatory and program management. Many Dark Horse consultants also bring experience from adjacent sectors, including traditional biologics, small molecules, medical devices, and management consulting. As a result, Dark Horse applies best practices from other industries to address the unique needs of its cell and gene therapy clients.

MINNEAPOLIS, MINNESOTA, August 7, 2019 — Arcline Investment Management ("Arcline"), a growth-oriented private equity firm with $1.5 billion of capital under management, today announced that it has acquired Pride Engineering, LLC ("Pride" or "the Company") from May River Capital. Pride is anticipated to be the first of several acquisitions as Arcline builds a specialty tooling platform across numerous industries.

Pride Engineering is the global leader in the design and manufacture of precision-engineered tooling, equipment, and aftermarket parts that are mission-critical to the aluminum beverage packaging manufacturing process. The Company's products generate significant return on investment for its customers by maximizing quality, productivity and operational uptime. Pride's products include tool packs, bottom formers, precision grinders, and most recently, SYNAPSE™, the Company's next generation internet of things solution.

Arcline commented, "We are in the early innings of a once-in-a-generation shift in the packaging industry — the large-scale substitution of single-use plastic containers toward more sustainable aluminum containers. We are committed to supporting the anticipated volume growth of Pride's customers by heavily investing in the Company's engineering and technology capabilities. Specifically, we plan to work with Pride to accelerate the rollout of its newest product, SYNAPSE™, that uses sensor-driven analytics to drive step-change quality and productivity improvements in our industry."

Greg Pickert, President and CEO of Pride, added, "We are excited to partner with Arcline, which shares our passion for supporting our customers' vision of advancing the adoption of environmentally favorable packaging. Arcline's experience in software and technology enablement will be a great asset as we further develop the next generation of connected tooling for our customers. We look forward to playing a key role in the sustainable packaging industry as we invest in our next phase of growth."

Lincoln International served as financial advisor to Arcline in connection with the acquisition.

About Arcline Investment Management
Arcline is a private equity firm with $1.5 billion in capital, investing in niche, market-leading companies that we are passionate about growing. We approach investments from multiple perspectives, but share a single vision — to identify and unlock the breakout potential in our companies. While we are deliberately sector generalists, some of our primary interest areas include Industrials, Technology, Life Sciences, and Specialty Chemicals. www.arcline.com

About Pride Engineering
Pride Engineering is a leader in design and manufacture of precision-engineered tooling, equipment, and parts that are mission-critical to the aluminum beverage packaging manufacturing process. Pride's products include tool packs, bottom formers, precision grinders, and connectivity solutions that enhance its customers' processes. The Company maintains a state-of-the-art manufacturing facility in Minneapolis, Minnesota. www.pridecan.com

NEWTOWN, PENNSYLVANIA, August 12, 2019 —Arcline Investment Management ("Arcline"), a growth oriented private equity firm with $1.5 billion of capital under management, today announced a strategic investment in Actera Ingredients ("Actera" or "the Company"). Actera is anticipated to be the first of several acquisitions as Arcline builds a bio-actives personal care platform.

Actera is a leading innovator of functional and sensory cosmetics ingredients, including bio-actives for hair and skin care as well as specialty personal care preservatives derived from nature. The Company's high-performance products, tested in clinical studies and in-vivo trials, allow their customers to make important beneficial claims about the efficacy of the ingredients in their proprietary formulations.

"We are very excited to partner with Arcline to support our growing actives portfolio and allow us to expand our capabilities and team to better serve customers," said Actera CEO Dan Winn, who prior to founding Actera, most recently led the personal care strategy for ingredients company Inolex. "This investment also enables us to further develop cutting-edge products that the beauty industry is demanding from ingredient suppliers. We like Arcline's commitment and approach to science-based market driven products."

Arcline commented, "Consumers are beginning to value and understand the science behind their personal care and beauty spend. The cosmetic industry is rapidly adapting with new sustainable chemistries and biologically-produced clean ingredients. Actera is at the forefront of this clean label movement and will provide us a platform to invest into this rapidly changing landscape."

About Arcline Investment Management
Arcline is a private equity firm with $1.5B in capital, investing in niche, market-leading companies that we are passionate about growing. We approach investments from multiple perspectives but share a single vision — to identify and unlock the breakout potential in our companies. Some of our primary areas of interest include Life Sciences, Industrials Technology, and Specialty Chemicals.

About Actera Ingredients
Actera offers a range of ingredient technologies for cosmetics, hair care, household, flavors and fragrances and related personal care uses. We are on the cutting edge of performance, clean label, natural, anti-aging and other defining trends that drive innovation in these markets.

BOCA RATON, FLORIDA, September 11, 2019 —Arcline Investment Management ("Arcline"), a growth oriented private equity firm with $1.5 billion of capital under management, today announced that it has acquired a majority interest in Akron Biotechnology LLC ("Akron" or "The Company"). Akron will continue to be led by Claudia Zylberberg, PhD, the Company's founder and CEO and a member of its Board of Directors.

Founded in 2006, Akron is a leading supplier of cGMP-compliant products and services critical for the production of advanced therapy medicinal products, including cell therapies, gene therapies and engineered tissues. Akron offers a variety of cGMP products, including cytokines and growth factors, cryopreservation solutions, and cell culture media supplements. Its service offerings include recombinant protein development, fill & finish, scaffold fabrication, and media development. Akron supplies many of the largest, fastest-growing, and most well-known therapeutics companies in the industry.

"We recognize that the cell and gene therapy industry has reached a critical juncture. With so many therapy developers progressing through advanced stages of clinical development, the demand for cGMP-grade materials will increase dramatically in the near future. We are delighted to partner with Arcline to substantially expand Akron's capacity to meet this growing demand for the benefit of the entire regenerative medicine industry and the patients it serves," Dr. Zylberberg said.

Arcline commented, "We are pleased to partner with the Akron team. Our long-term alliance with the Company once again demonstrates Arcline's steadfast commitment to the emergent regenerative medicine industry. Given its focus on upstream cGMP solutions, Akron is an ideal platform investment opportunity in the cell and gene therapy space."

Arcline plans to work with the Akron team to organically build out its capabilities and pursue targeted complementary acquisitions within the cell and gene therapy manufacturing tools, ancillary materials and services continuum. Areas of interest include downstream technologies such as testing, quality control, purification, and fill & finish in addition to product categories such as disposables, human primary cells, viral/non-viral transduction, plasmid DNA, and clinical grade tools for CRISPR gene editing.

Dark Horse Consulting Group, the leading global consultancy practice specializing in cell and gene therapy product development, provided advice and assistance to Arcline in connection with the investment. Arcline formed a strategic partnership with Dark Horse Consulting Group in July 2019.

About Arcline Investment Management
Arcline is a private equity firm with $1.5 billion in capital, investing in niche, market-leading companies that we are passionate about growing. We approach investments from multiple perspectives but share a single vision – to identify and unlock the breakout potential in our companies. Some of our primary interest areas include Life Sciences, Industrials, Technology, and Specialty Chemicals.

About Akron Biotechnology
Akron is a leading materials manufacturer and services provider to the regenerative medicine industry, accelerating the development and commercialization of advanced therapies. Founded by Claudia Zylberberg, PhD in 2006, Akron is an ISO 13485-certified company that operates in line with cGMPs and international standards, enabling advanced therapy developers to de-risk their supply chains and facilitate regulatory approval. The company's unique business model emphasizes knowledge, flexibility, and unparalleled service—from development through commercialization. For more information, please visit us at www.akronbiotech.com.